Bavarian Nordic Strengthens Global Mpox Vaccine Supply Chain with Africa Collaboration

Bavarian Nordic A/S collaborates with African and global stakeholders to ensure equitable access to its Mpox vaccine. The company is expanding its manufacturing network to Africa, working with WHO on regulatory paths, and conducting clinical studies to extend vaccine use to adolescents and children.

Bavarian Nordic A/S has issued a statement on the supply of its Mpox vaccine, emphasizing its ongoing collaboration with African and global stakeholders.

The company announced a strong partnership with Africa CDC, promising not only vaccine supply but also an extension of its manufacturing network into Africa. This collaboration seeks to ensure equitable access to the vaccine.

Working in tandem with the WHO, Bavarian Nordic is striving to gain regulatory approval to expand vaccine accessibility to all countries. The company is also moving forward with clinical studies aimed at extending the vaccine's use to adolescents and children.

(With inputs from agencies.)